AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7751994 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms HB vaccine (Group C)
Number of subjects: 171
Study 7751994 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 171
Study 2077437 — intervention group
Group type: EXPERIMENTAL
Intervention: desglycinamide-(arg8) vasopressin (DGAVP) 2 mg, nasal route
Number of subjects: 12
Study 2077437 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 7022423 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 18
Study 7022423 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 18
Study 7022423 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide
Number of subjects: 18
Study 7022423 — intervention group
Group type: COMPARATOR
Intervention: Bumetanide vs Bendrofluazide
Number of subjects: 18
Study 31498950 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 2 mg administered as three loading doses every 4 weeks, then every 8 weeks until week 48
Number of subjects: 18
Study 29283292 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning resistance training
Number of subjects: 25
Study 29283292 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon resistance training
Number of subjects: 25
Study 29283292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 25
Study 29283292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-training acute loading
Number of subjects: 25
Study 29283292 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training acute loading in morning group
Number of subjects: 25
Study 29283292 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training acute loading in all groups
Number of subjects: 25
Study 29283292 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting cortisol
Number of subjects: 25
Study 29283292 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting testosterone
Number of subjects: 25
Study 25803657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical-spine rotation active joint-position sense (AJPS) at end-range of motion (60°)
Number of subjects: 53
Study 25803657 — intervention group
Group type: COMPARATOR
Intervention: Cervical-spine rotation active joint-position sense (AJPS) at mid-range of motion (30°)
Number of subjects: 53
Study 25255447 — intervention group
Group type: EXPERIMENTAL
Intervention: LD-aminopterin (0.007, 0.014, 0.021 mg/kg once-weekly)
Number of subjects: 75
Study 25255447 — intervention group
Group type: EXPERIMENTAL
Intervention: LD-aminopterin (0.007 mg/kg twice-weekly)
Number of subjects: 75
Study 25255447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 22696863 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% timolol eye gel
Number of subjects: 25
Study 22696863 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol eye drop
Number of subjects: 25
Study 20822191 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally vulnerable (EV) gamblers
Number of subjects: 229
Study 20822191 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisocial impulsive (AI) gamblers
Number of subjects: 229
Study 20822191 — intervention group
Group type: EXPERIMENTAL
Intervention: AI and EV gamblers
Number of subjects: 229
Study 20822191 — intervention group
Group type: EXPERIMENTAL
Intervention: All three subtypes (AI, EV, BC)
Number of subjects: 229
Study 20822191 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways subtypes
Number of subjects: 229
Study 17393018 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy (25 microg 17beta‐estradiol/125 microg norethisterone acetate applied every 3-4 days)
Number of subjects: 344
Study 17393018 — intervention group
Group type: COMPARATOR
Intervention: Oral hormone therapy (estradiol 1 mg and NETA 0.5 mg given once daily)
Number of subjects: 344
Study 15803450 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood methods to estimate the effect of intervention in the context of mixture distributions
Number of subjects: 0
Study 11965609 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y DOTATOC
Number of subjects: 256
Study 9624598 — intervention group
Group type: EXPERIMENTAL
Intervention: hexarelin + placebo
Number of subjects: 7
Study 9624598 — intervention group
Group type: EXPERIMENTAL
Intervention: hexarelin + TRH
Number of subjects: 7
Study 9624598 — intervention group
Group type: COMPARATOR
Intervention: TRH + placebo
Number of subjects: 7
Study 7519693 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg/o.d.)
Number of subjects: 20
Study 7519693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2497985 — intervention group
Group type: EXPERIMENTAL
Intervention: Minitran
Number of subjects: 65
Study 2497985 — intervention group
Group type: COMPARATOR
Intervention: Nitro-Dur II (ND II)
Number of subjects: 65
Study 2497985 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 65
Study 30913304 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus ziv-aflibercept (4 mg/kg every 2 weeks)
Number of subjects: 64
Study 30913304 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 plus placebo
Number of subjects: 64
Study 28163068 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) treatment on one side of the face
Number of subjects: 20
Study 28163068 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment on the other side of the face
Number of subjects: 20
Study 26759214 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (25 mg once daily)
Number of subjects: 491
Study 26759214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study 24734338 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-link semi cement application
Number of subjects: 25
Study 24734338 — intervention group
Group type: COMPARATOR
Intervention: Traditional burs or Piezosurgery device
Number of subjects: 25
Study 20861750 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC) 2 g daily
Number of subjects: 62
Study 20861750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 18302285 — intervention group
Group type: EXPERIMENTAL
Intervention: Debio‐025 (1200 mg twice daily for 14 days)
Number of subjects: 0
Study 18302285 — intervention group
Group type: EXPERIMENTAL
Intervention: Debio‐025
Number of subjects: 0
Study 17201845 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at sedative doses
Number of subjects: 0
Study 17201845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14627865 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 49)
Number of subjects: 152
Study 14627865 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg transdermal 17beta‐estradiol (tE2, n = 33)
Number of subjects: 152
Study 14627865 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral 17beta‐estradiol (oE2, n = 37)
Number of subjects: 152
Study 14627865 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral 17beta‐estradiol combined with 25 microg gestodene (oE2 + G, n = 33)
Number of subjects: 152
Study 10725476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal indomethacin (200 mg)
Number of subjects: 46
Study 10725476 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal plus oral indomethacin (200 mg)
Number of subjects: 46
Study 8870161 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootstrap method that resamples clusters
Number of subjects: 10
Study 8870161 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood based on the normal mixed linear model
Number of subjects: 10
Study 8870161 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-stage method
Number of subjects: 10
Study 8870161 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equations
Number of subjects: 10
Study 8870161 — intervention group
Group type: COMPARATOR
Intervention: All four methods
Number of subjects: 10
Study 8504041 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 15+, broad‐spectrum, water‐resistant sunscreen cream
Number of subjects: 603
Study 8504041 — intervention group
Group type: COMPARATOR
Intervention: Cream base without active ingredients (Control)
Number of subjects: 603
Study 3551494 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar diet (5% of daily carbohydrate intake)
Number of subjects: 22
Study 3551494 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar + fructose diet (1 g of fructose/kg body weight, max 30 g/d)
Number of subjects: 22
Study 3551494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no guar supplementation)
Number of subjects: 22
Study 31965073 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health-supported lifestyle intervention
Number of subjects: 0
Study 31965073 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 29430845 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counselling
Number of subjects: 367
Study 29430845 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 367
Study 27298740 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta-tACS (6 Hz) for 20 minutes during implicit language learning
Number of subjects: 2
Study 27298740 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 2
Study 25807130 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal capsaicin (LC) 0.025%
Number of subjects: 13
Study 25807130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 21986721 — intervention group
Group type: EXPERIMENTAL
Intervention: URMEL-ICE intervention
Number of subjects: 365
Study 21680251 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care intervention (n = 123)
Number of subjects: 500
Study 21680251 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n = 127)
Number of subjects: 500
Study 21680251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondepressed patients (n = 250)
Number of subjects: 500
Study 19892055 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (worksite health education, nutritional counseling, smoking cessation counseling, physical activity promotion, selected physician referral, and other health counseling)
Number of subjects: 339
Study 19892055 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention
Number of subjects: 339
Study 19892055 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 339
Study 16537665 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 20506
Study 16537665 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 20506
Study 12752017 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care (IC)
Number of subjects: 84
Study 12752017 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study 11083131 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg day(‐1))
Number of subjects: 31
Study 11083131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9332632 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated NIH Stroke Scale based on facial palsy, motor arm, and dysarthria
Number of subjects: 299
Study 9332632 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed Out-of-hospital NIH Stroke Scale consisting of facial palsy, motor arm, and abnormal speech
Number of subjects: 299
Study 9332632 — intervention group
Group type: COMPARATOR
Intervention: Non-stroke patients
Number of subjects: 299
Study 8437068 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine 0.25%, 0.7 mL/kg
Number of subjects: 100
Study 8437068 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 3743795 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) treatment
Number of subjects: 0
Study 3743795 — intervention group
Group type: COMPARATOR
Intervention: Follicle aspiration
Number of subjects: 0
Study 3743795 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle aspiration and CC use
Number of subjects: 0
Study 3743795 — intervention group
Group type: COMPARATOR
Intervention: No CC treatment
Number of subjects: 0
Study 3743795 — intervention group
Group type: COMPARATOR
Intervention: Follicle aspiration or general anesthesia
Number of subjects: 0
Study 30025522 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (250 mg/day) plus Vitamin E (400 IU/day)
Number of subjects: 60
Study 30025522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27660192 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab (16 cycles of 7.5 mg/kg bevacizumab by intravenous infusion over 90 min on day 1 of each cycle)
Number of subjects: 1941
Study 27660192 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (1250 mg/m2 twice daily for 14 days followed by a break for 7 days for 8 cycles)
Number of subjects: 1941
Study 27660192 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab
Number of subjects: 1941
Study 27660192 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 1941
Study 24768895 — intervention group
Group type: EXPERIMENTAL
Intervention: MSG broth (0.5 g/100 ml)
Number of subjects: 86
Study 24768895 — intervention group
Group type: EXPERIMENTAL
Intervention: MSG+ broth (0.05 g/100 ml)
Number of subjects: 86
Study 24768895 — intervention group
Group type: COMPARATOR
Intervention: Control preload (low-energy chicken flavor broth, 200 ml)
Number of subjects: 86
Study 22475864 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 μg hemagglutinin antigen
Number of subjects: 408
Study 22475864 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg hemagglutinin antigen
Number of subjects: 408
Study 22475864 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 408
Study 20417423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl, 1 microg/kg, and ketamine, 0.5 mg/kg (group FK)
Number of subjects: 80
Study 20417423 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl, 1 microg/kg, and normal saline solution (group F)
Number of subjects: 80
Study 18600492 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-monocysteine (ZMC) 25 mg twice daily
Number of subjects: 80
Study 18600492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15810046 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative duplex imaging (group 1; 166 legs)
Number of subjects: 293
Study 15810046 — intervention group
Group type: COMPARATOR
Intervention: No preoperative duplex imaging (group 2; 177 legs)
Number of subjects: 293
Study 14508828 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive nomogram incorporating clinical, laboratory, and TRUS data
Number of subjects: 1237
Study 14508828 — intervention group
Group type: COMPARATOR
Intervention: Prediction based on PSA alone
Number of subjects: 1237
Study 12022177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea polyphenols (TP) 600 mg/d orally
Number of subjects: 40
Study 12022177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 8685327 — intervention group
Group type: EXPERIMENTAL
Intervention: BIP gun
Number of subjects: 0
Study 8685327 — intervention group
Group type: EXPERIMENTAL
Intervention: Manan gun
Number of subjects: 0
Study 8685327 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy gun
Number of subjects: 0
Study 8685327 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAP gun
Number of subjects: 0
Study 8685327 — intervention group
Group type: EXPERIMENTAL
Intervention: Temno gun
Number of subjects: 0
Study 8685327 — intervention group
Group type: EXPERIMENTAL
Intervention: BIP gun (breast parenchyma model)
Number of subjects: 0
Study 8685327 — intervention group
Group type: EXPERIMENTAL
Intervention: Manan gun (breast parenchyma model)
Number of subjects: 0
Study 8685327 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy gun (breast parenchyma model)
Number of subjects: 0
Study 8685327 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAP gun (breast parenchyma model)
Number of subjects: 0
Study 8685327 — intervention group
Group type: EXPERIMENTAL
Intervention: Temno gun (breast parenchyma model)
Number of subjects: 0
Study 8685327 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopty gun (breast parenchyma model)
Number of subjects: 0
Study 8685327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-Cut gun (breast parenchyma model)
Number of subjects: 0
Study 1376694 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetorphan (200 mg)
Number of subjects: 11
Study 1376694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3903709 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 78
Study 3903709 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 78
Study 30719817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.1 mg kg-1 hr-1)
Number of subjects: 70
Study 30719817 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 70
Study 29420994 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Theanine
Number of subjects: 9
Study 29420994 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Theanine-Caffeine combination
Number of subjects: 9
Study 29420994 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 9
Study 26914113 — intervention group
Group type: EXPERIMENTAL
Intervention: SCUBE‐1
Number of subjects: 90
Study 26914113 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD40L
Number of subjects: 90
Study 25331395 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration and bone graft therapy
Number of subjects: 38
Study 25331395 — intervention group
Group type: COMPARATOR
Intervention: Flap surgery
Number of subjects: 38
Study 22316337 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention (EI)
Number of subjects: 120
Study 22316337 — intervention group
Group type: COMPARATOR
Intervention: Education and nutrition intervention (EIN)
Number of subjects: 120
Study 22316337 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 20589924 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 45
Study 20589924 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of caffeine
Number of subjects: 45
Study 20589924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 18540714 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy Challenge (EC) intervention
Number of subjects: 217
Study 18540714 — intervention group
Group type: COMPARATOR
Intervention: CD-ROM alcohol education
Number of subjects: 217
Study 18540714 — intervention group
Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 217
Study 16029638 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TME and anal sphincter preservation combined with brachytherapy by (125)I seed implantation (group B)
Number of subjects: 76
Study 16029638 — intervention group
Group type: COMPARATOR
Intervention: Rectostomy and anal sphincter preservation (group A)
Number of subjects: 76
Study 12635747 — intervention group
Group type: EXPERIMENTAL
Intervention: human menopausal gonadotropin (hMG)
Number of subjects: 99
Study 12635747 — intervention group
Group type: COMPARATOR
Intervention: highly purified follicle stimulating hormone (pFSH)
Number of subjects: 99
Study 10335496 — intervention group
Group type: EXPERIMENTAL
Intervention: remacemide hydrochloride
Number of subjects: 340
Study 10335496 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 340
Study 10335496 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 340
Study 7579435 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase 1,500,000 IU over 1 hour followed by a 48-hour placebo infusion
Number of subjects: 64
Study 7579435 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase 250,000 IU over 1 hour followed by a continuous infusion of 100,000 IU per hour over 48 hours
Number of subjects: 64
Study 7579435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 2010447 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (10 mg/L in crystalloid potassium cardioplegia)
Number of subjects: 12
Study 2010447 — intervention group
Group type: COMPARATOR
Intervention: Control (same cardioplegia without diltiazem)
Number of subjects: 12
Study 6838742 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine anaesthesia
Number of subjects: 40
Study 6838742 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptanaesthesia
Number of subjects: 40
Study 6838742 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 29505552 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 1875
Study 29505552 — intervention group
Group type: COMPARATOR
Intervention: Water Immersion (WI)
Number of subjects: 1875
Study 29505552 — intervention group
Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 1875
Study 29536389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide
Number of subjects: 200
Study 29536389 — intervention group
Group type: COMPARATOR
Intervention: Lanthanum carbonate
Number of subjects: 200
Study 27060836 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous peginterferon beta‐1a (125 μg s.c.)
Number of subjects: 30
Study 27060836 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous interferon beta‐1a (44 μg s.c. three times per week)
Number of subjects: 30
Study 27060836 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous peginterferon beta‐1a
Number of subjects: 30
Study 24952693 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 813
Study 24952693 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 813
Study 24952693 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of ST2 and galectin-3
Number of subjects: 813
Study 22240389 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast dissolving oral film containing 4 mg dexamethasone
Number of subjects: 0